Endpoints News
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex
Maze Therapeutics unveiled positive mid-stage data for its genetic kidney disease drug that could spell major competition for Vertex Pharmaceuticals’ program that has the same target.
Maze’s candidate, codenamed MZE829, produced an average 35.6% reduction …